SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:eed86879-d261-4f2e-8595-08e91d23e268"
 

Search: onr:"swepub:oai:lup.lub.lu.se:eed86879-d261-4f2e-8595-08e91d23e268" > Low serum level of ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Brenne, AT (author)

Low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma

  • Article/chapterEnglish2004

Publisher, publication year, extent ...

  • 2004

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:eed86879-d261-4f2e-8595-08e91d23e268
  • https://lup.lub.lu.se/record/899022URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-24035URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Background and Objectives. Thalidomide modulates the production of tumor necrosis factor (TNF-alpha). Soluble TNF receptors, TNFR p55 and TNFR p75, modify TNF-a activity. In this study, we explored the relation between soluble TNF receptors and outcome in patients with advanced multiple myeloma treated with thalidomide. Design and Methods. The levels of soluble TNF receptor p55 and p75 were assessed in serum from 34 myeloma patients with relapsed or refractory disease before starting thalidomide treatment. Serial measurements were performed for 16 patients in serum collected during treatment. Results. The pre-treatment serum level of soluble TNFR p55 in thalidomide responders was significantly lower than that in non-responders (median 1.75 ng/mL (range 1.19-2.84) vs. 2.79 ng/mL (1.36-5.51), p=0.004). The levels of p55 declined significantly during treatment. The levels of p75 showed the same pattern as p55, but the differences were not significant. The median survival of myeloma patients with pre-treatment levels of p55 less than or equal to 2.79 ng/mL was 404 days; the median survival of patients with pre-treatment levels less than or equal to 2.79 ng/mL was shorter (65 days, log-rank test p=0.02). Interpretation and Conclusions. We conclude that soluble TNFR p55 is an adverse prognostic factor in myeloma patients with relapsed or refractory disease treated with thalidomide. Patients with a low pre-treatment level of this receptor have a better response rate and a longer overall survival.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Romstad, LH (author)
  • Gimsing, P (author)
  • Juliusson, Gunnar,1954-Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Hematologiska kliniken US(Swepub:liu)gunju78 (author)
  • Turesson, IngemarLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine(Swepub:lu)medf-itu (author)
  • Romundstad, P (author)
  • Borset, M (author)
  • Sundan, A (author)
  • Waage, A (author)
  • Linköpings universitetHälsouniversitetet (creator_code:org_t)

Related titles

  • In:Haematologica89:5, s. 552-5561592-87210390-6078

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Brenne, AT
Romstad, LH
Gimsing, P
Juliusson, Gunna ...
Turesson, Ingema ...
Romundstad, P
show more...
Borset, M
Sundan, A
Waage, A
show less...
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
and Hematology
Articles in the publication
Haematologica
By the university
Lund University
Linköping University

Search outside SwePub

Wikipedia about the author:
AT_Brenne
Brenne, AT
en

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view